Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.41 +1.9%	$3.28	$2.63 ▼ $4.73	$651.99M	1.45	987,911 shs	454,833 shs
KALV KalVista Pharmaceuticals	$13.07 +0.5%	$11.66	$7.30 ▼ $15.50	$649.79M	0.39	405,375 shs	300,171 shs
PRQR ProQR Therapeutics	$1.63 +5.5%	$1.62	$1.07 ▼ $4.62	$170.97M	0.25	599,868 shs	1.04 million shs
TRVI Trevi Therapeutics	$6.37 -3.3%	$5.75	$2.30 ▼ $7.39	$614.12M	0.41	1.13 million shs	3.08 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.52%	+4.05%	-4.57%	-0.30%	+22.34%
KALV KalVista Pharmaceuticals	+0.08%	+8.24%	+8.97%	+46.56%	+20.59%
PRQR ProQR Therapeutics	+7.69%	+16.67%	+10.00%	-24.88%	-20.62%
TRVI Trevi Therapeutics	+1.85%	+9.47%	+1.38%	+66.84%	+137.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.9959 of 5 stars	3.5	0.0	0.0	2.6	2.5	0.6
KALV KalVista Pharmaceuticals	4.3525 of 5 stars	4.6	0.0	4.4	3.0	2.5	0.6
PRQR ProQR Therapeutics	3.1733 of 5 stars	4.6	4.0	0.0	3.5	0.0	0.0
TRVI Trevi Therapeutics	3.4948 of 5 stars	4.7	2.0	0.0	2.5	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	61.53% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	90.00% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.75	438.46% Upside
TRVI Trevi Therapeutics	3.30	Buy	$17.56	175.53% Upside

Current Analyst Ratings Breakdown

Latest PRQR, KALV, ABUS, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
4/29/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/26/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/26/2025	KALV KalVista Pharmaceuticals	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/19/2025	TRVI Trevi Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $20.00
3/19/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.50 ➝ $12.50
3/19/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
3/19/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $24.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	105.65	N/A	N/A	$0.63 per share	5.40
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
PRQR ProQR Therapeutics	$18.91M	9.04	N/A	N/A	$0.55 per share	2.95
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.38	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	5/1/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-103.92%	-88.06%	7/10/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.43M	-$0.34	N/A	N/A	N/A	-134.31%	-71.58%	-19.70%	5/8/2025 (Estimated)
TRVI Trevi Therapeutics	-$29.07M	-$0.47	N/A	N/A	N/A	N/A	-63.31%	-57.06%	5/6/2025 (Estimated)

Latest PRQR, KALV, ABUS, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	N/A	N/A	N/A	$4.90 million	N/A
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	N/A	N/A	N/A	$2.54 million	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
KALV KalVista Pharmaceuticals	N/A	6.87	6.87
PRQR ProQR Therapeutics	N/A	2.33	2.33
TRVI Trevi Therapeutics	N/A	7.38	7.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
KALV KalVista Pharmaceuticals	N/A
PRQR ProQR Therapeutics	32.65%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
KALV KalVista Pharmaceuticals	10.50%
PRQR ProQR Therapeutics	8.40%
TRVI Trevi Therapeutics	24.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.48 million	181.91 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.23 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	74.82 million	Optionable
TRVI Trevi Therapeutics	20	96.68 million	58.13 million	Optionable

PRQR, KALV, ABUS, and TRVI Headlines

Recent News About These Companies

XTX Topco Ltd Makes New Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 28 at 3:58 AM | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Silverarc Capital Management LLC

April 24, 2025 | marketbeat.com

Vivo Capital LLC Boosts Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 23, 2025 | marketbeat.com

Trevi Therapeutics management to meet virtually with B. Riley

April 22, 2025 | markets.businessinsider.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by Analysts

April 14, 2025 | marketbeat.com

Trevi Therapeutics management to meet with Cantor Fitzgerald

April 11, 2025 | markets.businessinsider.com

Traders Purchase Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)

April 11, 2025 | marketbeat.com

Landscape Capital Management L.L.C. Has $215,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 11, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from Needham & Company LLC

April 10, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 9.3% - Should You Sell?

April 10, 2025 | marketbeat.com

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

April 3, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Down - Here's What Happened

April 2, 2025 | marketbeat.com

Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Rises By 23.5%

April 2, 2025 | marketbeat.com

Earnings call transcript: Trevi Therapeutics Q4 2024 reports mixed results

March 20, 2025 | uk.investing.com

TREVI THERAPEUTICS Earnings Results: $TRVI Reports Quarterly Earnings

March 20, 2025 | nasdaq.com

Trevi Therapeutics price target raised to $20 from $11 at B. Riley

March 19, 2025 | markets.businessinsider.com

B.Riley Financial Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)

March 19, 2025 | markets.businessinsider.com

Trevi Therapeutics reports Q4 EPS (11c), consensus (12c)

March 19, 2025 | markets.businessinsider.com

Trevi Therapeutics options imply 7.8% move in share price post-earnings

March 19, 2025 | markets.businessinsider.com

Trevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move Forward

March 18, 2025 | marketwatch.com

Trevi Therapeutics added to Analyst Current Favorites list at Raymond James

March 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, KALV, ABUS, and TRVI Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.40 +0.07 (+1.95%)

As of 03:49 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

KalVista Pharmaceuticals NASDAQ:KALV

$13.07 +0.07 (+0.54%)

As of 03:48 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

ProQR Therapeutics NASDAQ:PRQR

$1.62 +0.09 (+5.52%)

As of 03:49 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Trevi Therapeutics NASDAQ:TRVI

$6.37 -0.22 (-3.28%)

As of 03:49 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time